Wednesday, October 30, 2024

Eli Lilly's quarter was messy. What to do with the stock is more clear-cut

We're upgrading our rating on the drugmaker to a buy-equivalent 1.
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

SGX NIFTY

Loading...

Ads Inside Post